IRAK4 kinase inhibitor

IRAK4 kinase inhibitors are a class of small molecule therapeutics designed to block the enzymatic activity of Interleukin-1 receptor-associated kinase 4 (IRAK4). IRAK4 is a critical serine/threonine kinase that functions as a key signaling node downstream of the MyD88 adapter protein, mediating signals from the Toll-like receptor (TLR) and Interleukin-1 receptor (IL-1R) families. Upon receptor activation, IRAK4 is recruited to the Myddosome complex, where its kinase activity triggers downstream signaling cascades, including the activation of NF-κB and MAP kinases. This process leads to the production of pro-inflammatory cytokines and chemokines. By inhibiting IRAK4 kinase activity, these compounds aim to suppress the inflammatory response in autoimmune and autoinflammatory diseases. Clinical and preclinical research has explored IRAK4 inhibitors for conditions such as systemic lupus erythematosus (SLE), rheumatoid arthritis, and hidradenitis suppurativa.

Other names

IRAK4 kinase inhibitorIRAK-4 kinase inhibitorIRAK 4 kinase inhibitorIRAK4 inhibitorIRAK-4 inhibitorIRAK 4 inhibitor